TOPICS FOR DISCUSSION

Similar documents
6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

Jesse K. McKenney, MD

Urinary Bladder, Ureter, and Renal Pelvis

A215- Urinary bladder cancer tissues

Carcinoma of the Urinary Bladder Histopathology

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)

The pathology of bladder cancer

UICC TNM 8 th Edition Errata

UICC TNM 8 th Edition Errata

Prognostic factors of genitourinary tumors: Do we have to care?

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Neoplasms of the Prostate and Bladder

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

Definition of Synoptic Reporting

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

The quintessential role of the surgical pathologist in

SEER Summary Stage Still Here!

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Urinary Bladder, Ureter, and Renal Pelvis

Male genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.


Staging for Residents, Nurses, and Multidisciplinary Health Care Team

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

Diagnosis, pathology and prognosis including variant pathology

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Carcinoma of the Renal Pelvis and Ureter Histopathology

BLADDER CANCER EPIDEMIOLOGY

Patient identifiers Date of request Accession/Laboratory number. TUMOUR FOCALITY (Note 4) (Note 3)

Staging and Grading Last Updated Friday, 14 November 2008

Large blocks in prostate and bladder pathology

GUIDELINES ON PROSTATE CANCER

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Genitourinary. Presentation Outline. Genitourinary System 12/14/2011. FCDS 2011 Educational Webcast Series December 15, 2011

The Urinary System Pearson Education, Inc.

Collaborative Staging

Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic

Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD

Glossary of Terms Primary Urethral Cancer

GUIDELINEs ON PROSTATE CANCER

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018

Staging and Treatment Update for Gynecologic Malignancies

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Supplemental Information

Prostate Case Scenario 1

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)

Urology An introduction to cut up DR J R GOEPEL

Q&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda

5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

46. Merkel Cell Carcinoma

Gastric Cancer Histopathology Reporting Proforma

Information for Patients. Primary urethral cancer. English

Bladder Cancer Guidelines

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates

BLADDER CANCER: PATIENT INFORMATION

CPC on Cervical Pathology

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

URINARY SYSTEM. These organs lie posterior or inferior to the. (membrane).

3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours

Protocol for the Examination of Specimens from Patients with Carcinoma of the Urinary Bladder

Prostate Cancer: Screening, Treatment, and Survivorship

Testicular Malignancies /8/15

Collection of Recorded Radiotherapy Seminars

Chapter 2. Understanding My Diagnosis

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

The importance of maximal restoration of peri-prostatic support

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

Essentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis

Protocol for the Examination of Specimens From Patients With Carcinoma of the Urethra and Periurethral Glands

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Disclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Immunohistochemistry and Bladder Tumours

Kidney Case 1 SURGICAL PATHOLOGY REPORT

The Role of the Pathologist Active Surveillance for Prostate Cancer

Copyright 2003 Pearson Education, Inc. publishing as Benjamin Cummings. Dr. Nabil Khouri

Protocol for the Examination of Specimens From Patients With Carcinoma of the Urinary Bladder

Transcription:

INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los Angeles, CA aminm@cshs.org TOPICS FOR DISCUSSION Discuss changes in pathologic staging categories in urologic malignancies in the 7 th edition (2011) AJCC Staging System, to be released later this year Select problematic areas: Prostate bladder neck involvement Urinary bladder determination of type of muscle invasion Urothelial carcinoma of prostate evaluation of prostatic stromal invasion PROSTATE SUMMARY OF CHANGES Extraprostatic invasion with microscopic bladder neck invasion (T4) is included with T3a Gleason Score now recognized as the preferred grading system Prognostic factors have been incorporated in the Anatomic Stage/Prognostic Groups Gleason Score Preoperative prostate specific antigen (PSA)

Group T N M PSA Gleason I T1a c T2a T1-2a PSA <10 PSA <10 PSA <X Gle < 6 Gle < 6 Gle X IIA T1a c PSA <20 Gle 7 T1a c PSA >10 <20 Gle < 6 T2a T2b T2b PSA <20 PSA <20 PSA X Gle < 7 Gle < 7 Any X IIB T2c T1 2 Any PSA PSA >20 Any Gle Any Gle T1 2 Any PSA Any Gle III T3a c Any PSA Any Gle IV T4 Any T Any T N1 Any N M1 Any PSA Any PSA Any PSA Any Gle Any Gle KIDNEY SUMMARY OF CHANGES T2 lesions have been divided into T2a (greater than 7 cm but less than or equal to 10 cm) and T2b (greater than 10 cm) Ipsilateral adrenal involvement is reclassified as T4 if contiguous invasion and M1 if not contiguous Renal vein involvement is reclassified as T3a Nodal involvement is simplified to vs. N1 Sixth edition Seventh edition T2: Tumor more than 7 cm in greatest dimension, limited to kidney T2: T2a (greater than 7 cm but less than or equal to 10 cm) T2b (greater than 10 cm)

National Cancer Database Renal Cell Carcinoma- Tumor size Nese N, Paner GP, Mallin K, Ritchey J, Stewart A, Amin MB. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. Ann Diagn Pathol. 2009 Feb;13(1):1-8. Size in cm Dx 1 Year 2 Years 3 Years 4 Years 5 Years <= 4.0 100 93.7 88.8 84.5 79.8 75.4 95% CI 74.6-76.1 4.1-7.0 95% CI 100 90.6 83.6 77.6 72.5 67.9 67.0-68.7 7.1-10.0 100 84.9 75.0 68.1 62.5 57.0 95% CI 55.9-58.1 >10.0 100 78.7 66.3 58.8 52.5 47.5 95% CI 46.1-48.9 Cummulative Survival Rate 100 90 80 70 60 50 40 30 20 10 0 Dx 1 Year 2 Years 3 Years 4 Years 5 Years Years From Diagnosis <=4 4.1-7 7.1-10 >10 NCDB- 47,909 cases URINARY BLADDER SUMMARY of CHANGES Subepithelial invasion of prostatic urethra is not pt4 disease. pt4 defined as prostatic stromal invasion (seminal vesicles, uterus, vagina, pelvic wall, and abdominal wall also qualify) Grading: a low and high grade designation will replace previous 4 grade system to match current WHO/International Society of Urologic Pathology (ISUP) recommended grading system Nodal involvement is simplified to N1 (single positive) and N2 (multiple positive) -instead of N1, N2, and N3 which had size criteria within

Sixth edition Seventh edition T4: tumor invades prostate, uterus, and vagina Subepithelial invasion of prostatic urethra is not pt4 disease Not pt4 disease RENAL PELVIS AND URETER SUMMARY OF CHANGES Grading: a low and high grade designation will replace previous 4 grade system to match current WHO/International Society of Urologic Pathology (ISUP) recommended grading system URETHRA SUMMARY OF CHANGES Urothelial (Transitional Cell) Carcinoma Of The Prostate pt1: Tumor invades urethral subepithelial connective tissue (for tumors involving prostatic urethra only)

PENIS SUMMARY OF CHANGES T1 has been subdivided into T1a and T1b based on the presence or absence of lymphovascular invasion or poorly differentiated cancers T3 category is limited to urethral invasion and prostatic invasion is now considered T4 7 th edition T1a: no LVI or PD histology T1b: LVI or PD histology

TESTIS SUMMARY OF CHANGES The definition of TNM and the Stage Grouping for this chapter has not changed from the Sixth Edition Staging of Bladder Cancer: Evaluation of Muscularis Propria Invasion No change in Seventh edition of AJCC

Dispersed or Scattered Discontinuous or Interrupted Continuous Absent M. mucosae muscle pattern -typical Wispy or thin muscle bundles, 71/150 (47%)

M. mucosae muscle pattern Hypertrophic Haphazard (33%) M. mucosae muscle pattern Hypertrophic M. propria-like (45%) Typical Hypertrophic-Haphazard Hypertrophic-M. propria-like

Typical pattern: Arranged in groups Distinct compact bundles Smooth outline of bundles Several layers both horizontally and vertically Muscularis propria 2 types of muscle - awareness important for pt staging LP inv. (M. mucosae)- pt1 M. propria inv. - pt2

Muscularis mucosa or muscularis propria?

Muscle Markers Smooth muscle actin (SMA) Desmin H-caldesmon Smooth muscle myosin heavy chain Smoothelin Contractile protein Fully differentiated muscle cells Hyperplastic muscularis mucosa negative to weak Diffuse positivity in muscularis propria 100% specificity with diffuse staining Hypertrophic muscularis mucosa

SMA Smoothelin Smoothelin

SMA M. Mucosae Smoothelin M. Mucosae M. Mucosae vs. M. Propria in TURBT

SMA Smoothelin M. Mucosae vs. M. Propria in TURBT

SMA Smoothelin: Negative Suggestive of M. Mucosae SMOOTHELIN at USCAP 2009 GP Paner, Platform Monday 9.30 - Confirms value of smoothelin in TURBT specimens. - IR retained in the background of thermal tissue injury & involvement by carcinoma Dvorakova et al, Poster Tuesday 9.30 am - Smoothelin proved to be a reliable marker S Khayyata et al, Poster Monday 1pm - Intensity and extent of smoothelin staining accurately distinguishes MP from MM in the intact bladder - Documentation of patterns of smoothelin expression is warranted - variable positivity in GU tract smooth muscle may help define functional status (ureter, bladder neck) &/or impact cancer staging (bladder, urachus)

Staging Issues in Urothelial Carcinoma of the Prostate UROTHELIAL CARCINOMA INVOLVING THE PROSTATE GLAND The prostate is involved in approximately 30% of patients with invasive bladder carcinoma Occasionally, urothelial carcinoma involving the prostate may be first documented on prostate biopsy Staging issues are problematic and not well covered in traditional text books INVOLVEMENT OF PROSTATE GLAND Direct invasion of prostate gland: pt4a of bladder cancer poor prognosis Urothelial CIS of urethra: if margin status (+), urethrectomy Involvement of prostatic glands without stromal invasion ( ptcis*): not adverse Involvement of seminal vesicle without stromal invasion: no risk of progression Involvement of prostate or seminal vesicle stroma ( pt2*): poor prognosis, metastasis *Staging for urothelial carcinoma of prostate

pt4 Bladder Carcinoma Direct extension of a urothelial carcinoma into prostatic stroma equates to pt4 disease- urinary bladder cancer staging system Extension of prostatic urethral urothelial carcinoma into prostatic stroma is not pt4 disease- pt2 by urothelial carcinoma of the prostate staging system

Bladder neck invasion- pt3a disease in AJCC, 7 th Edition

Bladder neck Histo-anatomy Most distal portion of bladder It merges with prostate gland in males It is formed by trigonal, detrusor, and urethral musculature; internal sphincter present in this region Devoid of glandular tissue- occasionally may have prostatic ducts/acini

Bladder neck Invasion of bladder neck interpreted as extension beyond prostate- pt4 PCa (AJCC, 6 th Edition) SEER Site specific coding guidelines- ICD 67.5 for bladder neck (Bladder: 67, Prostate: 61) Multiple recent studies have documented that microscopic bladder neck involvement has outcome different from PCa involving rectum or striated sphincter Microscopic bladder neck invasion defined as pt3 disease in AJCC, 7 th Edition Microscopic Bladder Neck Invasion (pt3 disease) Microscopic involvement of muscular wall of bladder neck by PCa Absence of prostatic glands in corresponding slide or prostate glands in stroma distinct from bladder neck muscle Handling of radical prostatectomy Prostate base (bladder neck) margininked and handled as a cone Microscopic sections- bladder neck tissue may or may not be presentdepends on Bladder neck sparing surgery Age of the patient Other surgical factors influencing dissection

Microscopic Bladder Neck Invasion (pt3 disease) Outcome of patients with bladder neck involvement is different from pt4 disease and similar to extraprostatic extension at other sites Prostate base (bladder neck ) margin- positive if tumor inked in coned prostate base and not if tumor in bladder neck muscle Prostate base (bladder neck ) margin- important adverse parameter- worse than other positive surgical margins